Henoch-Schönlein purpura (HSP), first recognised by Heberden in 1801, is a systemic, IgA mediated vasculitis of small vessels that is usually self-limiting but may progress to gastrointestinal bleeding, intussusception, and nephropathy. A third of patients will experience recurrences.¹ Currently treatment is confined to rest, analgesia, and steroids for refractory abdominal pain,² and immunosuppressants for complications, especially renal disease. Original reports, predominantly in adults, show that the symptoms of purpuric rash, abdominal pain, and arthritis in HSP respond to treatment with dapsone.^3–, …